Zhang Bo, Li Guang-Tian, Ye Yang
Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Department of Emergency, the Fifth Hospital of Harbin City, Harbin 150088, China.
Comb Chem High Throughput Screen. 2024 Jun 6. doi: 10.2174/0113862073295270240522104058.
QiShenYiQi (QSYQ) has shown promise in the treatment of blood-brain barrier (BBB) damage following stroke. However, the identification of its bioactive components and the underlying molecular mechanisms of action remain unknown. This study aimed to investigate the active ingredients and mechanisms involved in the inhibitory effects of QSYQ on BBB damage after ischemic stroke based on network pharmacology and experimental verification.
The chemical composition and target information of QSYQ were obtained from the Traditional Chinese Medicine Systems Pharmacology and Analysis Platform. BBB injury-related targets were identified by screening databases, and the overlapping targets with QSYQ were collected. Cytoscape software was utilized to construct protein-protein interaction (PPI) networks. Molecular docking analysis was conducted using AutoDock software. Animal experiments were carried out to verify the protective effect of QSYQ on BBB and explore potential molecular mechanisms.
A total of 131 active ingredients in QSYQ and 154 common targets related to QSYQ and BBB damage were identified. Analysis of the PPI network revealed key targets including ALB, INS, ACTB, TP53, and CASP3 against BBB injury. Molecular docking analysis indicated favorable binding interactions between dihydrotanshinlactone, tanshinone IIA, salviolone, and their respective target proteins, such as FOS, INS, CASP3, and JUN. In animal experiments, QSYQ demonstrated effective inhibition of BBB damage, and this effect may be attributed to the regulation of ALB, INS, TP53, and CASP3.
This study provides intriguing insights into the mechanisms by which QSYQ protects against BBB injury following ischemic stroke. Key targets, including ALB, INS, TP53, and CASP3, could be potentially involved in the beneficial effects of QSYQ.
芪参益气滴丸（QSYQ）在治疗中风后血脑屏障（BBB）损伤方面已显示出前景。然而，其生物活性成分的鉴定及其潜在的分子作用机制仍不清楚。本研究旨在基于网络药理学和实验验证，探讨芪参益气滴丸对缺血性中风后血脑屏障损伤抑制作用的活性成分及机制。
从中药系统药理学分析平台获取芪参益气滴丸的化学成分和靶点信息。通过筛选数据库确定血脑屏障损伤相关靶点，并收集与芪参益气滴丸的重叠靶点。利用Cytoscape软件构建蛋白质-蛋白质相互作用（PPI）网络。使用AutoDock软件进行分子对接分析。进行动物实验以验证芪参益气滴丸对血脑屏障的保护作用，并探索潜在的分子机制。
鉴定出芪参益气滴丸中的131种活性成分以及与芪参益气滴丸和血脑屏障损伤相关的154个共同靶点。对PPI网络的分析揭示了针对血脑屏障损伤的关键靶点，包括ALB、INS、ACTB、TP53和CASP3。分子对接分析表明二氢丹参内酯、丹参酮IIA、丹参醇与其各自的靶蛋白（如FOS、INS、CASP3和JUN）之间具有良好的结合相互作用。在动物实验中，芪参益气滴丸显示出对血脑屏障损伤的有效抑制作用，且这种作用可能归因于对ALB、INS、TP53和CASP3的调节。
本研究为芪参益气滴丸预防缺血性中风后血脑屏障损伤的机制提供了有趣的见解。包括ALB、INS、TP53和CASP3在内的关键靶点可能参与了芪参益气滴丸的有益作用。
